Free Trial
→ Why I went to Mount Rushmore (From Stansberry Research) (Ad)tc pixel Free FATE Stock Alerts

Fate Therapeutics (FATE) Competitors

Fate Therapeutics logo
$2.18 +0.05 (+2.35%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$2.17 -0.01 (-0.60%)
As of 10/9/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

FATE vs. VOR, MNKD, MGTX, CVAC, and AKTS

Should you buy Fate Therapeutics stock or one of its competitors? Fate Therapeutics's main competitors and comparable companies include Vor Biopharma (VOR), MannKind (MNKD), MeiraGTx (MGTX), CureVac (CVAC), and Aktis Oncology (AKTS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Fate Therapeutics compare to Vor Biopharma?

Vor Biopharma (NASDAQ:VOR) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Vor Biopharma currently has a consensus price target of $41.71, suggesting a potential upside of 109.62%. Fate Therapeutics has a consensus price target of $5.90, suggesting a potential upside of 170.64%. Given Fate Therapeutics' higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than Vor Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vor Biopharma
0 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
2.90
Fate Therapeutics
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38

Vor Biopharma has a beta of 1.78, indicating that its stock price is 78% more volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.52, indicating that its stock price is 152% more volatile than the broader market.

Vor Biopharma has higher earnings, but lower revenue than Fate Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vor BiopharmaN/AN/AN/AN/AN/A
Fate Therapeutics$6.65M39.28-$136.32M-$1.05N/A

Vor Biopharma has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,941.09%. Vor Biopharma's return on equity of 0.00% beat Fate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Vor BiopharmaN/A N/A N/A
Fate Therapeutics -1,941.09%-65.08%-41.73%

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by company insiders. Comparatively, 4.7% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Fate Therapeutics had 3 more articles in the media than Vor Biopharma. MarketBeat recorded 7 mentions for Fate Therapeutics and 4 mentions for Vor Biopharma. Fate Therapeutics' average media sentiment score of 0.54 beat Vor Biopharma's score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vor Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Fate Therapeutics
1 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Fate Therapeutics beats Vor Biopharma on 7 of the 13 factors compared between the two stocks.

How does Fate Therapeutics compare to MannKind?

Fate Therapeutics (NASDAQ:FATE) and MannKind (NASDAQ:MNKD) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by insiders. Comparatively, 2.6% of MannKind shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Fate Therapeutics presently has a consensus target price of $5.90, indicating a potential upside of 170.64%. MannKind has a consensus target price of $7.84, indicating a potential upside of 138.41%. Given Fate Therapeutics' higher probable upside, analysts clearly believe Fate Therapeutics is more favorable than MannKind.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fate Therapeutics
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38
MannKind
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60

MannKind has a net margin of -11.08% compared to Fate Therapeutics' net margin of -1,941.09%. MannKind's return on equity of 0.00% beat Fate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Fate Therapeutics-1,941.09% -65.08% -41.73%
MannKind -11.08%N/A -6.31%

In the previous week, MannKind had 3 more articles in the media than Fate Therapeutics. MarketBeat recorded 10 mentions for MannKind and 7 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 0.54 beat MannKind's score of 0.53 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fate Therapeutics
1 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MannKind
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Fate Therapeutics has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market. Comparatively, MannKind has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

MannKind has higher revenue and earnings than Fate Therapeutics. MannKind is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fate Therapeutics$6.65M39.28-$136.32M-$1.05N/A
MannKind$348.97M3.03$5.86M-$0.13N/A

Summary

MannKind beats Fate Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Fate Therapeutics compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 7.4% of MeiraGTx shares are owned by insiders. Comparatively, 4.7% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MeiraGTx has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.52, indicating that its stock price is 152% more volatile than the broader market.

MeiraGTx presently has a consensus price target of $24.71, suggesting a potential upside of 131.19%. Fate Therapeutics has a consensus price target of $5.90, suggesting a potential upside of 170.64%. Given Fate Therapeutics' higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than MeiraGTx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MeiraGTx
0 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.78
Fate Therapeutics
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38

MeiraGTx has a net margin of 19.87% compared to Fate Therapeutics' net margin of -1,941.09%. MeiraGTx's return on equity of 283.85% beat Fate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MeiraGTx19.87% 283.85% 29.39%
Fate Therapeutics -1,941.09%-65.08%-41.73%

In the previous week, Fate Therapeutics had 1 more articles in the media than MeiraGTx. MarketBeat recorded 7 mentions for Fate Therapeutics and 6 mentions for MeiraGTx. Fate Therapeutics' average media sentiment score of 0.54 beat MeiraGTx's score of 0.38 indicating that Fate Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MeiraGTx
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Fate Therapeutics
1 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

MeiraGTx has higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MeiraGTx$81.39M12.61-$114.20M$0.7115.06
Fate Therapeutics$6.65M39.28-$136.32M-$1.05N/A

Summary

MeiraGTx beats Fate Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Fate Therapeutics compare to CureVac?

Fate Therapeutics (NASDAQ:FATE) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, Fate Therapeutics had 6 more articles in the media than CureVac. MarketBeat recorded 7 mentions for Fate Therapeutics and 1 mentions for CureVac. Fate Therapeutics' average media sentiment score of 0.54 beat CureVac's score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fate Therapeutics
1 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CureVac
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

CureVac has a net margin of 199.92% compared to Fate Therapeutics' net margin of -1,941.09%. CureVac's return on equity of -23.03% beat Fate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Fate Therapeutics-1,941.09% -65.08% -41.73%
CureVac 199.92%-23.03%-19.09%

Fate Therapeutics has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

Fate Therapeutics currently has a consensus target price of $5.90, suggesting a potential upside of 170.64%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Fate Therapeutics is more favorable than CureVac.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fate Therapeutics
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38
CureVac
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by insiders. Comparatively, 2.2% of CureVac shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

CureVac has higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fate Therapeutics$6.65M39.28-$136.32M-$1.05N/A
CureVac$70.74M14.78$175.50M$0.726.47

Summary

Fate Therapeutics beats CureVac on 9 of the 16 factors compared between the two stocks.

How does Fate Therapeutics compare to Aktis Oncology?

Fate Therapeutics (NASDAQ:FATE) and Aktis Oncology (NASDAQ:AKTS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 4.7% of Fate Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Aktis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Fate Therapeutics and Fate Therapeutics both had 7 articles in the media. Fate Therapeutics' average media sentiment score of 0.54 beat Aktis Oncology's score of 0.01 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fate Therapeutics
1 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aktis Oncology
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Fate Therapeutics presently has a consensus price target of $5.90, indicating a potential upside of 170.64%. Aktis Oncology has a consensus price target of $35.63, indicating a potential upside of 96.28%. Given Fate Therapeutics' higher possible upside, equities research analysts plainly believe Fate Therapeutics is more favorable than Aktis Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fate Therapeutics
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38
Aktis Oncology
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.91

Aktis Oncology has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,941.09%. Aktis Oncology's return on equity of 0.00% beat Fate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Fate Therapeutics-1,941.09% -65.08% -41.73%
Aktis Oncology N/A N/A N/A

Aktis Oncology has lower revenue, but higher earnings than Fate Therapeutics. Aktis Oncology is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fate Therapeutics$6.65M39.28-$136.32M-$1.05N/A
Aktis Oncology$6.50M150.09-$63.73M-$0.82N/A

Summary

Aktis Oncology beats Fate Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Fate Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FATE vs. The Competition

Export
MetricFate TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$255.22M$3.86B$7.17B$13.21B
Dividend YieldN/A3.66%2.53%16.37%
P/E Ratio-2.0813.42274.1526.16
Price / Sales39.281,234.39635.99107.44
Price / CashN/A116.5676.3853.09
Price / Book1.2117.1711.226.33
Net Income-$136.32M-$22.69M$3.50B$382.15M
7 Day Performance-6.03%-1.34%-0.90%-1.40%
1 Month Performance-6.44%-8.45%-4.44%-3.47%
1 Year Performance33.33%14.03%7.02%1.19%

Fate Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FATE
Fate Therapeutics
2.7816 of 5 stars		$2.18
+2.3%		$5.90
+170.6%		+35.4%$255.22M$6.65MN/A161
VOR
Vor Biopharma
1.9479 of 5 stars		$18.31
-1.1%		$41.71
+127.8%		-37.3%$1.10BN/AN/A76
MNKD
MannKind
3.9278 of 5 stars		$3.35
+0.3%		$8.34
+149.1%		-36.0%$1.07B$348.97MN/A592
MGTX
MeiraGTx
3.1496 of 5 stars		$11.11
+1.8%		$24.71
+122.5%		+22.0%$1.05B$81.39M15.65393
CVAC
CureVac
0.0725 of 5 stars		$4.66
flat		N/AN/A$1.05B$70.74M6.47880

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:FATE) was last updated on 10/10/2026 by MarketBeat.com Staff.
From Our Partners
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
Inside the Options Play With a High Historical Win Rate
Ian Cooper's newest strategy targets triple-digit returns in just 9 days. It doesn't work every time, but a 73...
TradeWins | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
A major gold reset could be closer than people think
For 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One...
Reagan Gold Group | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel